Comparison of the ability between dual-energy X-ray absorptiometry and bioelectrical impedance analysis for diagnosing low skeletal muscle mass and sarcopenia in patients with chronic liver disease
- PMID: 39511932
- DOI: 10.1111/jgh.16806
Comparison of the ability between dual-energy X-ray absorptiometry and bioelectrical impedance analysis for diagnosing low skeletal muscle mass and sarcopenia in patients with chronic liver disease
Abstract
Background and aim: Sarcopenia and osteoporosis adversely impact the clinical outcomes of patients with chronic liver disease (CLD). The Japan Society of Hepatology (JSH) sarcopenia criteria utilize bioelectrical impedance analysis (BIA) for assessing muscle mass rather than dual-energy X-ray absorptiometry (DXA), which can simultaneously diagnose these comorbidities. We investigated the correlations and interchangeability between the appendicular skeletal muscle mass index (ASMI) values determined using BIA and DXA and evaluated the diagnostic ability of DXA for sarcopenia and osteosarcopenia in patients with CLD.
Methods: This cross-sectional study included 173 patients with CLD. Sarcopenia was defined as low ASMIBIA according to the JSH and Asian Working Group for Sarcopenia (AWGS) criteria (ASMIBIA cutoff) or low ASMIDXA according to the AWGS criteria (ASMIDXA cutoff) and low handgrip strength. For women, a provisional cutoff value was set for ASMIDXA using the ASMIBIA cutoff (ASMIDXA-altered cutoff).
Results: We found that ASMIBIA and ASMIDXA were significantly correlated (r = 0.921; P < 0.001). The Bland-Altman plots demonstrated substantial agreement between ASMIBIA and ASMIDXA, with a mean difference of 0.0116 kg/m2. The prevalence rates of sarcopenia and osteosarcopenia diagnosed using the ASMIBIA cutoff were 26.0% and 17.3%, respectively. The kappa coefficients for the prevalence of sarcopenia and osteosarcopenia were 0.759 and 0.775 between ASMIBIA cutoff and ASMIDXA cutoff and 0.780 and 0.806 between ASMIBIA cutoff and ASMIDXA-altered cutoff, respectively.
Conclusions: The utilization of DXA can facilitate the comprehensive assessment and management of musculoskeletal comorbidities in patients with CLD.
Keywords: bioelectrical impedance analysis; chronic liver disease; dual‐energy X‐ray absorptiometry; osteoporosis; sarcopenia.
© 2024 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
References
-
- Saeki C, Tsubota A. Influencing factors and molecular pathogenesis of sarcopenia and osteosarcopenia in chronic liver disease. Life 2021; 11: 899.
-
- Zeng X, Shi ZW, Yu JJ et al. Sarcopenia as a prognostic predictor of liver cirrhosis: a multicentre study in China. J. Cachexia. Sarcopenia Muscle 2021; 12: 1948–1958.
-
- Iacob S, Mina V, Mandea M et al. Assessment of sarcopenia related quality of life using SarQoL® questionnaire in patients with liver cirrhosis. Front. Nutr. 2022; 9: 774044.
-
- Tantai X, Liu Y, Yeo YH et al. Effect of sarcopenia on survival in patients with cirrhosis: a meta‐analysis. J. Hepatol. 2022; 76: 588–599.
-
- Kikuchi N, Uojima H, Hidaka H et al. Prospective study for an independent predictor of prognosis in liver cirrhosis based on the new sarcopenia criteria produced by the Japan Society of Hepatology. Hepatol. Res. 2021; 51: 968–978.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
